LRRK2 and Parkinson disease: Co-IP experiments showed that R1728H resulted in a ~50% decrease in binding with endogenous 14-3-3 relative to WT (Fig. 6c), highlighting the critical impact of these interactions on LRRK2 kinase activity and PD pathogenesis.